Search Here

The U.S Food and Drug Administration recently announced the approval of a treatment for night-time urination condition. The FDA-approved treatment is now made available to people suffering from a condition where they wake at least two times at night just to urinate only upon the prescription of their attending physician.

Noctiva is a nasal spray for adults suffering a condition known as nocturnal polyuria. Nocturnal polyuria is described as the overproduction of urine at nighttime leading to people suffering from such condition to wake up at least two times at night just to pee. But the FDA emphasized that Noctiva is not a treatment for all kinds of night-time urination conditions. The attending physician should first be able to determine the cause of the night-time urination and whether prescribing Noctiva is right for their patient or not.

As it is, nocturia, or the condition where an individual often wakes up at night just to urinate, can be caused by a number of conditions such as congestive heart failure, diabetes, bladder and prostrate problems as well as effects of some medications. So it is important that the attending physician should be able to determine the underlying causes of nocturia as Noctiva can only treat individuals suffering specifically from nocturnal polyuria.

The Noctiva nasal spray is used daily 30 minutes before the person goes to bed. Noctiva increases the absorption of water by the kidneys thereby reducing the amount of urine produced by the body.

The nasal spray comes with a medication guide and a boxed warming as it causes the drop of sodium levels in the blood (hyponatremia). Other side effects of Noctiva include increased blood pressure, back pain, congestion, colds, bronchitis, and nose bleeds.

The effectivity of Noctiva as a treatment for nocturnal polyuria was established from 1,045 50-year-olds and older patients during two 12-week randomized trials. Noctiva was found to cut in half the number of times the patients wake up at night to pee.